Intravascular devices for continuous glucose monitoring are promising tools for the follow up and treatment of diabetic patients. Limiting the inflammatory response to the implanted devices in order to achieve better biocompatibility is a critical challenge. Herein we report on the production and the characterization of gold surfaces covalently derivatized with the peptide α-alpha-melanocyte stimulating hormone (α-MSH), with a quantifiable surface density. In vitro study demonstrated that the tethered α-MSH is able to decrease the expression of an inflammatory cytokine produced by endothelial cells.
Citation: Le Saux G, Plawinski L, Nlate S, Ripoche J, Buffeteau T, Durrieu M-C (2016) Beneficial Effect of Covalently Grafted α-MSH on Endothelial Release of Inflammatory Mediators for Applications in Implantable Devices. PLoS ONE 11(3): e0150706. https://doi.org/10.1371/journal.pone.0150706
Editor: Gualtiero I. Colombo, Centro Cardiologico Monzino IRCCS, ITALY
Received: September 21, 2015; Accepted: February 18, 2016; Published: March 3, 2016
Copyright: © 2016 Le Saux et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work has benefited from a French State grant (reference ANR-10-LABX-0042- AMADEus) managed by the French National Research Agency under the initiative of excellence IdEx Bordeaux program (reference n°ANR-10-IDEX-0003-02).
Competing interests: The authors have declared that no competing interests exist.
Diabetes currently affects more than 300 million people around the world and is expected to become the 7th cause of death by 2030 . Patients suffering from diabetes are highly affected by damaging and life-threatening complications  and a tighter control of glucose levels is critical to avoid these . To date, the most common method to monitor blood glucose level is the use of portable amperometric sensors with the drawback that it only gives a “snapshot” of the blood glucose levels and necessitates daily repeats of blood sample collection by finger pricking. Continuous glucose monitoring (CGM) could revolutionize the monitoring and management of glycaemia [4, 5]. Today, CGM is performed by quantifying glucose levels within the interstitial fluid, using either non-invasive techniques such as optical and transdermal sensors  or invasive subcutaneous sensors . There is, however, a lag between blood and interstitial fluid glucose levels  which makes difficult a fast and accurate response to changing glucose concentrations. In the case of subcutaneous sensors, in addition to problems with accuracy , biocompatibility is an issue that remains to be fully addressed  especially with regards to foreign body reaction  which has a negative impact on the subcutaneous sensor’s longevity and performance [11–13]. A less common method is the direct monitoring of blood glucose levels using a closed loop system, consisting of an insulin delivery pump coupled with an intravenous implantable sensor . The intravenous glucose sensor, which was introduced by Armour et al. , was initially thought to be dangerous because of clotting issues. However, Armour et al. showed higher accuracy and encouraging results regarding safety as they delivered real-time blood glucose data with no sign of thrombosis on the animals used in the study.
One issue that remains to be addressed is the role of endothelial cells in the host inflammatory response to the implanted sensor . Endothelial cells are strongly involved in vascular inflammation in part by producing pro-inflammatory cytokines, including interleukin-6 (IL-6), which in turn amplifies leukocyte recruitment [17, 18]. The extent of inflammation is correlated to the expression of cytokines  and can eventually lead to a loss in sensor function . To overcome this, a wide range of approaches has been sought to optimize host inflammatory response . Several options are currently in development such as passive anti-inflammatory coatings , biocompatible coatings made of natural substances like alginate , chitosan , collagen  or hyaluronan  or synthetic hydrogels such as poly(hydroxyethyl methacrylate) , poly(ethylene glycol) [28, 29] and poly(lactic-co-glycolic acid) . However, these methods may either trigger an immunogenic response  or display poor adhesion and biocompatibility . Hence the need for the development of active anti-inflammatory strategies . Coatings delivering anti-inflammatory agents such as dexamethasone [34, 35] or vitamin E  offer an interactive and directed approach to modulate cell behavior, however the efficacy and lifetime of such systems remain limited by poor control over the release kinetics  and by the quantity of bioactive molecules they can supply .
Using surface immobilized molecules as an alternate strategy could be beneficial for the design of implants with long term anti-inflammatory properties. A candidate with great potential is the alpha-melanocyte stimulating hormone, or α-MSH. This tridecapeptide sequence of the melanocortin family is produced by many different cell types and is known to have potent anti-inflammatory properties . α-MSH exerts its activity via a group of melanocortin receptors (MC-R) belonging to the family of G-protein-coupled receptors . In addition to the central nervous system and melanocytes, MC-R have been detected recently on adipocytes, keratinocytes, immunocompetent as well as inflammatory cells, fibroblasts and importantly, endothelial cells [39, 41, 42].
With regards to electrochemical glucose monitoring, the choice of material is crucial and for this, gold based implants hold great promise . First, gold is the conductive material par excellence. Second, gold is widely used in medical devices due to its excellent biocompatibility . Third, gold implants can be ameliorated by functionalizing their surface with bioactive molecules for the control of a desired biological response . Importantly, the bio-interface should be homogeneous, it should have a controlled surface density of active molecules and should avoid undesired interactions with cells [45, 46].
Given the anti-inflammatory action of soluble α-MSH in vitro and that it was shown that α-MSH remained active in reducing the inflammatory response of neurons, when immobilized on surfaces , we sought to investigate its impact on endothelial behavior. In the present work, we covalently immobilized α-MSH onto gold using well defined self-assembled monolayers of carboxyethyl terminated hepta (ethylene glycol) (see Fig 1 for a depiction of the surfaces used in this study). The produced surfaces were characterized in depth by X-ray Photoelectron Spectroscopy (XPS) and Polarization Modulation Infrared Reflection-Absorption Spectroscopy (PM-IRRAS) to assess their quality and to quantify the effective grafting of α-MSH. We then investigated the impact of the α-MSH modified substrates on lipopolysaccharide (LPS) induced inflammatory response of human umbilical vein endothelial cells.
Schematic depiction of bare gold (A) before and (B) after modification with HS-EO7-COOH; “EO7-COOH” surface. After (C) activation of the carboxyl moieties with EDC/NHS, (D) the surface is functionalized with maleimide; “EO7-maleimide” surface. Finally, (E) α-MSH is immobilized on the surface via thiol-maleimide chemistry; “EO7-MSH” surface.
Materials and chemicals
All chemicals were used as received without further purification. Ultra-pure water (18.2 MΩ.cm; Elga) was used for surface cleaning. O-(2-Carboxyethyl)-O′-(2-mercaptoethyl)heptaethylene glycol (≥95%; HS-EO7-COOH), N-(2-Aminoethyl)maleimide trifluoroacetate salt (≥98%), N-hydroxysuccinimide (98%; NHS), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (≥98%; EDC), 2-(N-Morpholino)ethanesulfonic acid hydrate (≥99.5%; MES), absolute ethanol (≥99.8%), methanol (≥99.6%) and sulfuric acid (85.0–98.0%) were purchased from Sigma-Aldrich, France. Hydrogen peroxide (35% w/w in water) was purchased from Alfa Aesar, Germany. Custom synthesized HS-CH2-CH2-CO-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 peptide (≥98%; α-MSH) was obtained from Genecust, Luxemburg. Gold coated glass slides (300 nm thickness evaporated gold on glass-plates with an intermediate layer of Cr/Ni) were purchased from Applications Couches Minces, Paris.
Preparation of SAMs on gold
The successive modification steps and resulting surfaces are schematically displayed in Fig 1. The formation of O-(2-Carboxyethyl)-O′-(2-mercaptoethyl)heptaethylene glycol derived self-assembled monolayers (SAMs) was performed according to the protocol provided by Sigma-Aldrich . Gold plated glass slides were cut into 1cm2 pieces for XPS and cell experiments or 4 cm2 for PM-IRRAS experiment and cleaned for 30 min in freshly prepared piranha solution (1:3 v/v H2O2 to H2SO4). After copious rinsing with, consecutively, ultra-pure water and absolute ethanol, the surfaces were immersed in a 20 mM solution of HS-EO7-COOH in absolute ethanol for 24 h. Subsequently, the samples were rinsed with absolute ethanol, sonicated for 2 min in fresh ethanol and dried under a stream of nitrogen. The produced surfaces are henceforth referred to as EO7-COOH (surface B in Fig 1).
Functionalization of gold surfaces with α-MSH
The EO7-COOH surfaces were immersed for 1 h in an aqueous solution of EDC, NHS and MES at concentrations of 0.2, 0.1, and 0.1 M respectively thus forming the succinimide activated EO7-COOH (Fig 1C). After copious rinsing with consecutively ultra-pure water and methanol, the surfaces were immersed for 12 h in a 10 mM methanolic solution of N-(2-Aminoethyl)maleimide trifluoroacetate salt to give EO7-maleimide (Fig 1D). The surfaces were then rinsed extensively with methanol, ethanol and water and immersed for 2 h in a 1 mM aqueous solution of the thiolated α-MSH (EO7-MSH surfaces, Fig 1E). After covalent immobilization, the surfaces were rinsed with ultra-pure water for 1 week under agitation in order to remove the physically adsorbed peptides.
X-ray Photoelectron spectroscopy (XPS).
A ThermoFisher Scientific K-ALPHA spectrometer was used for surface analysis with a monochromatized AlKα source (hν = 1486.6 eV) and a 200 micron spot size. A pressure of 10−7 Pa was maintained in the chamber during analysis. The survey spectra (0–1350eV) were obtained with a constant pass energy of 200 eV and high resolution spectra at a constant pass energy of 40eV. Charge neutralization was activated even for conductive samples. High resolution spectra were fitted and quantified using the AVANTAGE software provided by ThermoFisher Scientific. Two samples per condition were prepared and three areas per sample were analyzed.
Polarization modulation-infrared reflection-adsorption spectroscopy (PM-IRRAS).
PM-IRRAS spectra were recorded on a ThermoNicolet Nexus 670 FTIR spectrometer at a resolution of 4 cm-1, by coadding several blocks of 1500 scans (30 minutes acquisition time). All spectra were collected in a dry-air atmosphere after 30 min of incubation in the chamber. Experiments were performed at an incidence angle of 75° using an external homemade goniometer reflection attachment . The infrared parallel beam was directed out of the spectrometer with an optional flipper mirror and made slightly convergent with a first BaF2 lens. The IR beam passed through a BaF2 wire grid polarizer (Specac) to select the p-polarized radiation and a ZnSe photoelastic modulator (PEM, Hinds Instruments, type III) which modulates the polarization of the beam at a high fixed frequency (74 KHz) between the parallel (p) and perpendicular (s) linear states. After reflection on the sample, the double modulated (in intensity and in polarization) infrared beam was focused with a second ZnSe lens onto a photovoltaic MCT detector (Kolmar Technologies, Model KV104) cooled at 77 K. In all experiments, the PEM was adjusted for a maximum efficiency at 2500 cm-1 to cover the mid-IR range in only one spectrum. For calibration measurements, a second linear polarizer (oriented parallel or perpendicular to the first preceding the PEM) was inserted between the sample and the second ZnSe lens. This procedure was used to calibrate and convert the PM-IRRAS signal in terms of the IRRAS signal (i.e., where Rp(d) and Rp(0) stand for the p-polarized reflectance of the film/substrate and bare substrate systems, respectively) [50, 51].Two samples per condition were prepared for PM-IRRAS analysis.
Human Umbilical Vein Endothelial Cells (HUVEC) were purchased from PromoCell, France and were cultured in PromoCell’s Endothelial Cell growth medium-2 at 37°C in 5% CO2. For experiments, cells were used between passages 4 and 6.
In a 24-well plate (Falcon Multiwell, Becton Dickinson & Co., NJ., USA), 500 μL of HUVEC suspension were incubated on the 1 cm2 surfaces at a density of 100000 cells per mL in serum free EBM-2 (Lonza, Switzerland) medium for 4–6 h. After this, the medium was replaced with EGM-2 BulletKit medium (Lonza, Switzerland) and cells were left to adhere for 24 h on the different surfaces used in this study. As a control, cells were also seeded cells on the plastic of the 24-well plate. To assess the specific effect of surface bound molecules on endothelial adhesion and inflammatory response, the Bulletkit aliquot which contained hydrocortisone was not added to the EGM-2 culture medium.
Immunofluorescent staining was performed to visualize the HUVECs on the different surfaces. After cell culture, cells were fixed by 4% (v/v) paraformaldehyde, permeabilized with 0.5% Triton-X 100, blocked with 1% bovine serum albumin (BSA) in PBS solution. The actin cytoskeleton was stained with Alexa Fluor® 488 phalloidin (Invitrogen, France). Nuclei were stained by mounting the samples with ProLong® Gold antifade reagent containing DAPI (Invitrogen, France). Cell adhesion was imaged using a Leica DM5500B epifluorescence microscope and quantified using the ImageJ software (NIH, http://rsb.info.nih.gov/ij/). Cell nuclei were counted for evaluation of adherent cell numbers. At least 10 fields at low magnification (10 X) on each surface were analyzed for this study.
HUVECs were replated onto the surfaces at a density of 50000 cells /cm2 according to the protocol stated previously. HUVEC were stimulated by adding 1 μg/mL of lipopolysaccharide (LPS, from E. Coli 0111:B4; Sigma-Aldrich, France) at the moment of replating. Negative control was performed by incubating cells in regular culture medium. IL-6 concentrations in the culture media of treated cells were measured using the human Instant IL-6 ELISA kit (eBioscience, Austria). IL-6 production was normalized to the number of adherent cells which was obtained as described above. All procedures were performed according to the manufacturer’s instructions. IL-6 levels where measured using an ELx808 microplate reader at 450 nm (Biotek, France).
All samples were assayed in triplicate and experiments were repeated 5 times. Statistical analysis was performed by analysis of variance. A Bonferroni multiple-comparison post-hoc test was also performed using the Prism software (GraphPad Software Inc., USA). P-values are reported for comparisons of interest.
Functionalization of the surfaces
Table 1 gives the changes in atomic proportions of surfaces used in this study.
C1s and N1s high resolution spectra of the EO7-maleimide and EO7-MSH surfaces.
To prevent any hydrolysis of the succinimidyl ester (Fig 1C) which would have lowered subsequent coupling yields, we proceeded directly to the maleimide and α-MSH modified surfaces. The C1s and N1s spectra of EO7-maleimide surface is shown on the left in Fig 2. In addition to the C-C at 284.6 eV, C-O at 286.3 and COOH carbons at 289.3, we observe the presence of new carbon species such as the C-CO at 285.3 eV, COOR at 288.4 eV and importantly the N-C = O carbons at 287.4 eV which are characteristic of expected chemical groups (Fig 1D). The N1s spectrum exhibits a contribution centered at 400 eV which corroborates the presence of N-C = O carbons. The experimental C/O and C/N ratios are 2.52 and 12.68, respectively (Table 1) which are close to the theoretical ratios of 2.27 and 12.5 in the case of a fully modified surface. The C1s and N1s spectra of the α-MSH modified surface are displayed in Fig 2 (right). In addition to the contributions of C-C at 284.8 eV, C-CO at 285.7 eV, C-O at 286.6 eV, COOR at 288.6 eV and COOH at 289.5 eV carbons, we observe the presence N-C = O at 287.6 eV as well as an increase in nitrogen from 2.5 to 4.7% (Table 1) which confirms the presence of peptides on the surface. For the EO7-MSH surface (Fig 1E), we found C/N and C/O ratios of 9.47 and 2.4 respectively (Table 1). These are significantly different to the theoretical ratios of 4.68 and 3.32 for a fully modified surface and thus suggest an incomplete modification of the surface. To assess the coupling efficiency, we took a closer look at the C/N ratios of theoretical and experimental surfaces. For a 100% percent coupling efficiency, or a surface fully modified with α-MSH, the expected C/N ratio is equal to 4.68. In contrast, a 0% coupling equates to having an EO7-maleimide only surface. We showed previously that the corresponding C/N was 12.68 experimentally. In the present case, a C/N ratio of 9.47 equates to a 40.1% coupling efficiency. We then used PM-IRRAS to confirm coupling yields and assess peptide surface densities.
The EO7-COOH was also analyzed by PM-IRRAS (see S1 Text), and showed that the surface is characteristic of crystalline PEO possessing a (7/2) helix structure with a succession of trans, trans and gauche conformations of the seven ethylene oxide units which turn two times per fiber period . Its symmetry properties are described by the D7 point group, allowing two active symmetry classes, in infrared spectroscopy, for each vibrational mode: A2 with the transition moment along the helix axis and E1 with the transition moment normal to the helix axis . The ethylene oxide helices are therefore oriented along an axis normal to the gold surface. The peptide modified surface EO7-MSH was also analyzed by PM-IRRAS (Fig 3A).
Spectra, expressed in IRRAS units, of (A) EO7-MSH surface and (B) compact monolayer of α-MSH.
Characteristic bands of the seven ethylene oxide (EO7) units are observed, such as at 2891 cm-1, corresponding to the C-H stretching of CH2 and at 1117 cm-1 assigned to the symmetric C-O-C stretching vibration. These bands are broader than for the crystalline PEO  and suggest a slight loss if EO7 backbone’s crystalline nature upon peptide grafting. The presence of the maleimide linker is confirmed by the two νipC = O and νopC = O bands at 1760 and 1700 cm-1, respectively. We also observe the appearance of amide bands at 1663 and 1549 cm-1 which account respectively for the amide I (νC = O) and amide II (δCNH + νC-N) modes of α-MSH. To assess the coupling efficiency, we compared the intensity of the amide bands from the PM-IRRAS spectrum of the EO7-MSH surface with that of a monolayer of our thiolated α-MSH that was directly deposited on gold (Fig 3B). The coupling yield of α-MSH the EO7-maleimide surface was found to be 50.1% which is substantially higher than the 40.1% found by XPS. Even though the underlying EO7-COOH surface’s near crystallinity is partially disrupted, it is possible to quantify the maximal surface density. Takahashi et al. described in detail the crystal structure of PEO, they observed that four helices pass through the PEO unit cell with parameters a = 8.05 Å, b = 13.04 Å, c (helix axis) = 19.48 Å and β = 125.4° . Assuming that the freestanding carboxyl units do not disrupt the PEO backbone, we can therefore calculate the number of available carboxyl molecules per mm2 (see S2 Text for calculation details). Ensues the amount of covalently grafted peptides per mm2 and thus the surface density which derives from the coupling yields obtained from XPS and PM-IRRAS. The surface density was found at 3.5 ± 0.5 pmol per mm2 for the EO7-MSH substrate.
Comparison of immobilized α-MSH versus soluble α-MSH
We investigated the potency of surface bound α-MSH compared to its soluble form. For this, it was imperative to quantify the total number of attached molecules per surface and to compare their efficacy with the same amount of molecules in solution. Knowing the surface density of α-MSH by PM-IRRAS, we could quantify the total number of available molecules for a given surface area. Considering a density of 3.5 pmol/mm2, the total number of MSH molecules for a 1 cm2 substrate is 350 pmoles. Given that 500 μL of cell medium is used per well for a 24 well plate, the equivalent number of soluble α-MSH is found for a concentration of 0.7 μM. The anti-inflammatory effect of soluble α-MSH was observed in vitro at concentrations from 1 nM to 1 μM . Therefore, we prepared cell culture media containing α-MSH with concentrations ranging from 0.2 nM to 10 μM, replated cells on plastic according to the protocol stated previously, stimulated cells with 1 μg/mL LPS and quantified IL-6 production by ELISA. Results are shown in Fig 4.
Effect of immobilized α-MSH (EO7-MHS) on LPS induced endothelial IL-6 production compared to cells re-plated onto culture dishes in culture medium containing either no soluble α-MSH (Control) or soluble α-MSH in concentration ranging from 0.2 nM to 10 μM. Error bars represent standard deviations. A Bonferroni test relative to EO7-MSH vs. other treatments was performed. Differences were considered significant for p<0.01 and marked with an asterisk. The number of replicates is n = 5.
As expected, the presence of α-MSH for concentrations as low as 0.2 nM significantly decreases IL-6 expression as shown by analysis of variance (p < .0001). We then compared EO7-MSH to the other treatments and found that, with the exception of MSH 10 μM condition, IL-6 production was significantly lower on the EO7-MSH (p<0.01).
Impact of the EO7-MSH surface on HUVEC IL-6 production
Prior to assessing HUVEC inflammatory response on the modified gold, cell adhesion was quantified on the surfaces used in this study (Fig 5).
(A) Epifluorescence images of Endothelial cells that were re-plated onto bare gold, EO7-COOH, EO7-MSH surfaces and culture dish (control) in culture medium containing 1μg/mL lipopolysaccharide (LPS+) or normal culture medium (LPS-). Cell were stained for actin (green) and nuclei (blue). (B) The fluorescence images were analyzed to determine the average number of adherent cells per mm2 after cells were adhered for 24h. Error bars represent standard deviations. A Bonferroni test relative to EO7-MSH LPS+ vs. other surfaces was performed. Differences were considered significant for p<0.01 and marked with an asterisk. The number of replicates is n = 5.
As seen in Fig 5A, HUVECs adhere on the surfaces and have a well-organized actin cytoskeleton. Overall, treatment with LPS does not appear to induce a change in cell morphology when compared to normal conditions. Cell adhesion per unit area is shown in Fig 5B. Analysis of variance showed significant differences in adhesion (p<0.003). Bonferroni post-hoc testing showed that, save for Bare gold LPS-, cell adhesion was highest for EO7-MSH surfaces, regardless of LPS treatment (p<0.01). Importantly, we observe no significant differences in adhesion on EO7-MSH surfaces between normal condition and LPS treated cell (p>0.99). We next investigated the effect of α-MSH grafted to surface on HUVEC (Fig 6).
IL-6 production of endothelial cells that were re-plated onto bare gold, EO7-COOH, EO7-MSH surfaces and culture dish (control) in culture medium containing 1μg/mL lipopolysaccharide (LPS+) or normal culture medium (LPS-). Error bars represent standard deviations. A Bonferroni test relative to EO7-MSH LPS+ vs. other LPS+ surfaces was performed. Differences were considered significant for p<0.05 and marked with an asterisk. Another post-hoc test comparing EO7-MSH LPS- to other LPS- surfaces was performed. Differences were considered significant for p<0.05 and marked with a section sign. The number of replicates is n = 5.
LPS, which is known to stimulate endothelial cell production of IL-6 , induced as expected a four-fold increase in IL-6 production by HUVECs in our controls on plastic culture dishes. Analysis of variance showed significant differences in IL-6 production (p<0.0001). Overall, IL-6 production was lower on all gold surfaces than on plastic culture dishes. Post-hoc analysis by Bonferroni showed that although IL-6 production is lower on EO7-MSH than on plastic for unstimulated cells (p<0.0001), the EO7-MSH surface did not fare significantly better than the bare gold or EO7-COOH surfaces (p>0.99). Conversely, in LPS stimulated cells, the lowest production of IL-6 is observed for the EO7-MSH surface when compared to the positive control (p<0.0001), the bare gold (p = 0.02), and EO7-COOH surface (p = 0.009) thus indicating anti-inflammatory activity of surface grafted α-MSH on HUVECs in pro-inflammatory conditions.
Gold substrates modified with bioactive molecules have been widely used to study cell behavior [45, 46]. It is generally assumed that the amount of peptide is proportional to both the gold surface area and to the bulk concentration. However, evaluating the surface density of active principles remains arduous. Numerous reports confirm the effective modification of the gold substrate with peptides but little to no information is given on the quantitative evaluation of surface density [56–58]. In contrast, when quantifying surface density is possible using STM on atomically smooth gold, it is difficult to implement this type of substrate for biological experiments . Others were able to quantify the interparticle distance of large dendrimers on gold by AFM  but since RGD clustering is known to strongly impact cell adhesion, the technique described by Lagunas et al. does not allow to investigate the impact of a known homogeneous peptide distribution on cell behavior. Using XPS and PM-IRRAS, we confirmed the effective grafting of α-MSH onto gold via a carboxyl terminated oligo(ethylene oxide) SAM. Serendipitously, we found that this SAM had the crystal structure of poly(ethylene oxide). In conjunction with the coupling yield obtained by XPS and PM-IRRAS, we therefore found a facile method to quantify the surface density of α-MSH which was found to be 3.5 pmol/mm2. This result is not only important because it distinguishes itself from the previously mentioned works where peptide density was only estimated but also because we were able to correlate this density with the activity of α-MSH either surface bound or in solution.
Since other molecules possess notable anti-inflammatory properties when grafted onto surfaces, it is of interest to compare their relative potency. For example, an in vivo study demonstrated the potency of superoxide dismutase in reducing foreign body reaction . However, in this case, surface density was only indirectly quantified, making a comparison impossible. In another case, catheters were modified with heparin with densities of 10 to 100 fmol/mm2 to block the adsorption of pro-coagulant proteins. Kim et al. studied the effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory response of LPS-stimulated human monocytes. They showed that a surface density of 35 fmol/mm2 inhibited monocyte IL-6 production by 50%. Considering that, in our case, a surface density of 3.5 pmol/mm2 of α-MSH reduced by 80% the production of IL-6 by LPS-stimulated HUVEC it appears that surface bound α-MSH fares at least as well as other anti-inflammatory molecules such as heparin or IL-1. However, because surface bound α-MSH with a density of 0.21 pmol/mm2, or 16 times less than in our case, reduced IL-1 and TNFα production by 2 to 3 orders of magnitude in microglia  it cannot be excluded that the potency of a given molecule is not uniform for all cell types.
To our knowledge, the impact of gold surfaces on endothelial IL-6 production in vitro is yet to be investigated. However, in an in vivo model, others showed that the nature of the surface modification elicited different level of inflammatory response, with bare gold inducing the lowest levels of inflammation . Our study did indeed show less IL-6 production by HUVEC plated on bare gold. In addition, Tanigawa et al. concluded that gold was a useful intravascular material as it reacts minimally with the vessel wall and induces lower thrombogenicity . It must be added that for cardiovascular applications, gold-coated stents do not decrease in-stent restenosis . Restenosis is the re-narrowing of the vessel consecutive to the placement of a stent in an artery and is known to be linked with inflammation  and an increase in IL-6 production . For the latter, the authors acknowledged that this increase in IL-6 production could stem from many different cell types and the sole contribution of endothelial cells was not quantified.
It is known that α-MSH in solution, in concentrations ranging from 10−8 to 10−12 M, has an anti-inflammatory effect on endothelial cells [40, 70]. This decrease in inflammation is done via the NF-κβ pathway in a dose dependent manner , and is observed by a reduction in the production of adhesion molecules  and pro-inflammatory cytokines . To be active, α-MSH specifically binds the MC-1 receptor which is present on the outer cell membrane . Therefore, and contrarily to glucocorticoids , α-MSH does not require internalization to exert its anti-inflammatory action. The grafting of MSH peptides onto gold surface without any loss of bioactivity was successfully achieved. As previously shown, binding biomolecules, such as peptides, directly to the biomaterial surface can result in steric hindrance, conformation change and loss of bioactivity . In this work, it was suggested that the nature of the spacer on top of which is attached the bioactive molecule is decisive in preserving bioactivity. Interestingly, poly(ethylene oxide), which constitutes the base layer in this work, could provide a relatively hydrophilic environment which is helpful in maintaining the bioactivity of certain molecules . This could explain why, in our case, α-MSH remains active in vitro. Accordingly, we observed that thiolated α-MSH directly grafted onto gold is not as efficient as EO7-MSH in reducing HUVEC IL-6 production (Fig A in S3 Text). However, it must be added that most of the work on α-MSH was previously performed in vivo and it was therefore important to investigate how culture media that contained soluble α-MSH in this range affected endothelial IL-6 production or not. As seen here, soluble α-MSH does decrease IL-6 production of endothelial cells by 40 to 80%, depending on the concentration. As a means of comparison, micromolar concentrations of dexamethasone, which is known for its anti-inflammatory properties, inhibited IL-6 production of LPS-stimulated HUVEC by 40–50%. This confirms that immobilized α-MSH is at least as efficient in reducing IL-6 production as its soluble form. Considering that longevity is an issue with an α-MSH releasing device , future in vivo testing of the efficacy of surface immobilized α-MSH is vital for applications where the long term control of endothelial inflammatory response is required.
In summary, we successfully modified and characterized gold surfaces with α-MSH. Due to the crystalline nature of the base layer, we were able to assess the peptide surface density quantitatively. We then showed that these surfaces can significantly decrease endothelial IL-6 production in response to LPS stimulation. Particular attention should be paid to the surface density of these molecules however. Indeed, as seen here, the effect of α-MSH is dose dependent and decreasing surface density could potentially elicit a less clear effect on endothelial cells. Further work on the impact of density as well as other cell responses to α-MSH and in vivo testing are required before direct applications in intravascular glucose sensors can be envisaged but also for subcutaneous sensors  and cardiovascular applications  which also require perennial anti-inflammatory coatings.
S1 Text. XPS and PM-IRRAS analyses of the EO7-COOH surfaces.
S2 Text. Determination of EO7-MSH surface density.
This work has benefited from a French State grant (reference ANR-10-LABX-0042-AMADEus) managed by the French National Research Agency under the initiative of excellence IdEx Bordeaux program (reference n°ANR-10-IDEX-0003-02). Authors would like to thank Dr. C. Labrugère (PLACAMAT, Université de Bordeaux) for her contribution in XPS data acquisition and analysis as well as A. Tanga (INSERM U1026) for participating in the scientific discussions. JR acknowledges the Association pour la Recherche en Néphrologie for support.
Conceived and designed the experiments: GLS LP SN JR TB MCD. Performed the experiments: GLS TB. Analyzed the data: GLS LP TB. Contributed reagents/materials/analysis tools: SN TB MCD. Wrote the paper: GLS JR TB MCD.
- 1. World Health Statistics 2012; World Health Organization: Geneva, Switzerland, 2012.
- 2. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med. 1993;329(14):977–86. pmid:8366922
- 3. Torimoto K, Okada Y, Mori H, Tanaka Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12(1):1.
- 4. Buckingham B, Caswell K, Wilson DM. Real-time continuous glucose monitoring. Current Opinion in Endocrinology, Diabetes and Obesity. 2007;14(4).
- 5. Koschwanez HE, Reichert WM. In vitro, in vivo and post explantation testing of glucose-detecting biosensors: Current methods and recommendations. Biomaterials. 2007;28(25):3687–703. pmid:17524479
- 6. Oliver NS, Toumazou C, Cass AEG, Johnston DG. Glucose sensors: a review of current and emerging technology. Diabet Med. 2009;26(3):197–210. pmid:19317813
- 7. Boyne MS, Silver DM, Kaplan J, Saudek CD. Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor. Diabetes. 2003;52(11):2790–4. pmid:14578298
- 8. Cengiz E, Tamborlane WV. A Tale of Two Compartments: Interstitial Versus Blood Glucose Monitoring. Diabetes Technol Ther. 2009;11(s1):S-11-S-6.
- 9. DeVries JH. Glucose Sensing Issues for the Artificial Pancreas. Journal of Diabetes Science and Technology. 2008;2(4):732–4. pmid:19885253
- 10. Nichols SP, Koh A, Storm WL, Shin JH, Schoenfisch MH. Biocompatible Materials for Continuous Glucose Monitoring Devices. Chem Rev. 2013.
- 11. Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials. 2003;24(19):3311–31. pmid:12763459
- 12. Wisniewski N, Moussy F, Reichert WM. Characterization of implantable biosensor membrane biofouling. Fresenius J Anal Chem. 2000;366(6–7):611–21. pmid:11225773
- 13. Gifford R, Kehoe JJ, Barnes SL, Kornilayev BA, Alterman MA, Wilson GS. Protein interactions with subcutaneously implanted biosensors. Biomaterials. 2006;27(12):2587–98. pmid:16364432
- 14. Renard E, Costalat G, Chevassus H, Bringer J. Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients. Diabetes Res Clin Pract. 2006;74, Supplement 2(0):S173–S7.
- 15. Armour JC, Lucisano JY, McKean BD, Gough DA. Application of Chronic Intravascular Blood Glucose Sensor in Dogs. Diabetes. 1990;39(12):1519–26. pmid:2245876
- 16. Norton LW, Koschwanez HE, Wisniewski NA, Klitzman B, Reichert WM. Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body response. Journal of Biomedical Materials Research Part A. 2007;81A(4):858–69.
- 17. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment. Immunity. 1997;6(3):315–25. pmid:9075932
- 18. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7(10):803–15. pmid:17893694
- 19. Cook-Mills JM, Deem TL. Active participation of endothelial cells in inflammation. J Leukoc Biol. 2005;77(4):487–95. pmid:15629883
- 20. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol. 2008;20(2):86–100. pmid:18162407
- 21. Morais JM, Papadimitrakopoulos F, Burgess DJ. Biomaterials/Tissue Interactions: Possible Solutions to Overcome Foreign Body Response. The AAPS Journal. 2010;12(2):188–96. pmid:20143194
- 22. Nishida K, Sakakida M, Ichinose K, Uemura T, Uehara M, Kajiwara K, et al. Development of a ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane, 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate. Med Prog Technol. 1995;21(2):91–103. pmid:7565400
- 23. de Vos P, Hoogmoed CG, Busscher HJ. Chemistry and biocompatibility of alginate-PLL capsules for immunoprotection of mammalian cells. J Biomed Mater Res. 2002;60(2):252–9. pmid:11857431
- 24. Hennink WE, van Nostrum CF. Novel crosslinking methods to design hydrogels. Advanced Drug Delivery Reviews. 2012;64, Supplement(0):223–36.
- 25. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Advanced Drug Delivery Reviews. 2003;55(12):1613–29. pmid:14623404
- 26. Schanté CE, Zuber G, Herlin C, Vandamme TF. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydr Polym. 2011;85(3):469–89.
- 27. Quinn CP, Pathak CP, Heller A, Hubbell JA. Photo-crosslinked copolymers of 2-hydroxyethyl methacrylate, poly(ethylene glycol) tetra-acrylate and ethylene dimethacrylate for improving biocompatibility of biosensors. Biomaterials. 1995;16(5):389–96. pmid:7662824
- 28. Quinn CAP, Connor RE, Heller A. Biocompatible, glucose-permeable hydrogel for in situ coating of implantable biosensors. Biomaterials. 1997;18(24):1665–70. pmid:9613815
- 29. Mowery KA, H. Schoenfisch M, Saavedra JE, Keefer LK, Meyerhoff ME. Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release. Biomaterials. 2000;21(1):9–21. pmid:10619674
- 30. Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, Dunn RL. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res. 1999;45(3):231–9. pmid:10397981
- 31. Williams DF. On the mechanisms of biocompatibility. Biomaterials. 2008;29(20):2941–53. pmid:18440630
- 32. Mendes SC, Reis RL, Bovell YP, Cunha AM, van Blitterswijk CA, de Bruijn JD. Biocompatibility testing of novel starch-based materials with potential application in orthopaedic surgery: a preliminary study. Biomaterials. 2001;22(14):2057–64. pmid:11426886
- 33. Bridges AW, García AJ. Anti-Inflammatory Polymeric Coatings for Implantable Biomaterials and Devices. J Diabetes Sci Technol. 2008;2(6):984–94. pmid:19885288
- 34. Norton LW, Park J, Babensee JE. Biomaterial adjuvant effect is attenuated by anti-inflammatory drug delivery or material selection. J Controlled Release. 2010;146(3):341–8.
- 35. Ito T, Fraser IP, Yeo Y, Highley CB, Bellas E, Kohane DS. Anti-inflammatory function of an in situ cross-linkable conjugate hydrogel of hyaluronic acid and dexamethasone. Biomaterials. 2007;28(10):1778–86. pmid:17204321
- 36. Hahn SK, Jelacic S, Maier RV, Stayton PS, Hoffman AS. Anti-inflammatory drug delivery from hyaluronic acid hydrogels. J Biomater Sci Polym Ed. 2004;15(9):1111–9. pmid:15503629
- 37. Patil SD, Papadimitrakopoulos F, Burgess DJ. Dexamethasone-Loaded Poly(Lactic-Co-Glycolic) Acid Microspheres/Poly(Vinyl Alcohol) Hydrogel Composite Coatings for Inflammation Control. Diabetes Technol Ther. 2004;6(6):887–97. pmid:15684644
- 38. Zhong Y, Bellamkonda RV. Controlled release of anti-inflammatory agent α-MSH from neural implants. J Controlled Release. 2005;106(3):309–18.
- 39. Luger TA, Brzoska T, Scholzen TE, Kalden DH, SunderkÖTter C, Armstrong C, et al. The Role of α-MSH as a Modulator of Cutaneous Inflammation. Ann NY Acad Sci. 2000;917(1):232–8.
- 40. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet. 1995;11(3):328–30. pmid:7581459
- 41. Starowicz K, Przewłocka B. The role of melanocortins and their receptors in inflammatory processes, nerve regeneration and nociception. Life Sci. 2003;73(7):823–47. pmid:12798410
- 42. Weng W-T, Huang S-C, Ma Y-L, Chan H-H, Lin S-W, Wu J-C, et al. α-Melanocyte-stimulating hormone inhibits angiogenesis through attenuation of VEGF/VEGFR2 signaling pathway. Biochimica et Biophysica Acta (BBA)—General Subjects. 2014;1840(6):1850–60.
- 43. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004;428(6982):487–92. pmid:15057821
- 44. Tirrell M, Kokkoli E, Biesalski M. The role of surface science in bioengineered materials. Surf Sci. 2002;500(1–3):61–83.
- 45. Mrksich M, Whitesides GM. Using Self-Assembled Monolayers to Understand the Interactions of Man-made Surfaces with Proteins and Cells. Annu Rev Biophys Biomol Struct. 1996;25(1):55–78.
- 46. Mrksich M. A surface chemistry approach to studying cell adhesion. Chem Soc Rev. 2000;29(4):267–73.
- 47. He W, McConnell GC, Schneider TM, Bellamkonda RV. A Novel Anti-inflammatory Surface for Neural Electrodes. Adv Mater. 2007;19(21):3529–33.
- 48. Preparing Self-Assembled Monolayers (SAMs), A Step-by-Step Guide for Solution-Based Self-Assembly. Available from: https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Aldrich/Instructions/1/al-266.pdf.
- 49. Buffeteau T, Desbat B, Turlet JM. Polarization Modulation FT-IR Spectroscopy of Surfaces and Ultra-thin Films: Experimental Procedure and Quantitative Analysis. Appl Spectrosc. 1991;45(3):380–9.
- 50. Buffeteau T, Desbat B, Blaudez D, Turlet JM. Calibration Procedure to Derive IRRAS Spectra from PM-IRRAS Spectra. Appl Spectrosc. 2000;54(11):1646–50.
- 51. Ramin MA, Le Bourdon G, Daugey N, Bennetau B, Vellutini L, Buffeteau T. PM-IRRAS Investigation of Self-Assembled Monolayers Grafted onto SiO2/Au Substrates. Langmuir. 2011;27(10):6076–84. pmid:21486004
- 52. Takahashi Y, Tadokoro H. Structural Studies of Polyethers, (-(CH2)m-O-)n. X. Crystal Structure of Poly(ethylene oxide). Macromolecules. 1973;6(5):672–5.
- 53. Siesler HW, Holland-Moritz K. Infrared and raman spectroscopy of polymers. Marcel Dekker, New York. 1980.
- 54. Brzoska T, Kalden DH, Scholzen T, Luger TA. Molecular Basis of the α-MSH/IL-1 Antagonism. Ann NY Acad Sci. 1999;885(1):230–8.
- 55. Jirik FR, Podor TJ, Hirano T, Kishimoto T, Loskutoff DJ, Carson DA, et al. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. The Journal of Immunology. 1989;142(1):144–7. pmid:2783321
- 56. Roberts C, Chen CS, Mrksich M, Martichonok V, Ingber DE, Whitesides GM. Using Mixed Self-Assembled Monolayers Presenting RGD and (EG)3OH Groups To Characterize Long-Term Attachment of Bovine Capillary Endothelial Cells to Surfaces. J Am Chem Soc. 1998;120(26):6548–55.
- 57. Chan EWL, Yousaf MN. Immobilization of Ligands with Precise Control of Density to Electroactive Surfaces. J Am Chem Soc. 2006;128(48):15542–6. pmid:17132022
- 58. Yea C-H, Lee B, Kim H, Kim S-U, El-Said WA, Min J, et al. The immobilization of animal cells using the cysteine-modified RGD oligopeptide. Ultramicroscopy. 2008;108(10):1144–7. pmid:18555614
- 59. Raigoza AF, Webb LJ. Molecularly Resolved Images of Peptide-Functionalized Gold Surfaces by Scanning Tunneling Microscopy. J Am Chem Soc. 2012;134(47):19354–7. pmid:23146081
- 60. Lagunas A, Castaño A, Artés J, Vida Y, Collado D, Pérez-Inestrosa E, et al. Large-scale dendrimer-based uneven nanopatterns for the study of local arginine-glycine-aspartic acid (RGD) density effects on cell adhesion. Nano Res. 2014;7(3):399–409.
- 61. Huang J, Gräter SV, Corbellini F, Rinck S, Bock E, Kemkemer R, et al. Impact of Order and Disorder in RGD Nanopatterns on Cell Adhesion. Nano Lett. 2009;9(3):1111–6. pmid:19206508
- 62. Udipi K, Ornberg RL, Thurmond KB, Settle SL, Forster D, Riley D. Modification of inflammatory response to implanted biomedical materials in vivo by surface bound superoxide dismutase mimics. J Biomed Mater Res. 2000;51(4):549–60. pmid:10880102
- 63. Du YJ, Brash JL, McClung G, Berry LR, Klement P, Chan AKC. Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex. Journal of Biomedical Materials Research Part A. 2007;80A(1):216–25.
- 64. Kim D-H, Smith JT, Chilkoti A, Reichert WM. The effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory profile of LPS-stimulated human monocytes. Biomaterials. 2007;28(23):3369–77. pmid:17482260
- 65. Barbosa JN, Barbosa MA, Águas AP. Inflammatory responses and cell adhesion to self-assembled monolayers of alkanethiolates on gold. Biomaterials. 2004;25(13):2557–63. pmid:14751741
- 66. Tanigawa N, Sawada S, Kobayashi M. Reaction of the aortic wall to six metallic stent materials. Acad Radiol. 1995;2(5):379–84. pmid:9419579
- 67. Dangas G, Kuepper F. Restenosis: Repeat Narrowing of a Coronary Artery: Prevention and Treatment. Circulation. 2002;105(22):2586–7. pmid:12045160
- 68. Shah PK. Inflammation, Neointimal Hyperplasia, and Restenosis: As the Leukocytes Roll, the Arteries Thicken. Circulation. 2003;107(17):2175–7. pmid:12732592
- 69. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart. 2000;84(1):83–7. pmid:10862597
- 70. Scholzen TE, Brzoska T, Kalden D-H, Hartmeyer M, Fastrich M, Luger TA, et al. Expression of Functional Melanocortin Receptors and Proopiomelanocortin Peptides by Human Dermal Microvascular Endothelial Cells. Ann NY Acad Sci. 1999;885(1):239–53.
- 71. Kalden DH, Scholzen T, Brzoska T, Luger TA. Mechanisms of the Antiinflammatory Effects of α-MSH: Role of Transcription Factor NF-κB and Adhesion Molecule Expression. Ann NY Acad Sci. 1999;885(1):254–61.
- 72. Scholzen TE, Sunderkatter C, Kalden DH, Brzoska T, Fastrich M, Fisbeck T, et al. Alpha-Melanocyte Stimulating Hormone Prevents Lipopolysaccharide-Induced Vasculitis by Down-Regulating Endothelial Cell Adhesion Molecule Expression. Endocrinology. 2003;144(1):360–70. pmid:12488365
- 73. Luger TA, Brzoska T. α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66(suppl_3):iii52–iii5. pmid:17934097
- 74. Yang Y-k, Dickinson C, Haskell-Luevano C, Gantz I. Molecular Basis for the Interaction of [Nle4,d-Phe7]Melanocyte Stimulating Hormone with the Human Melanocortin-1 Receptor (Melanocyte α-MSH Receptor). J Biol Chem. 1997;272(37):23000–10. pmid:9287296
- 75. Schoneveld OJLM, Gaemers IC, Lamers WH. Mechanisms of glucocorticoid signalling. Biochimica et Biophysica Acta (BBA)—Gene Structure and Expression. 2004;1680(2):114–28.
- 76. Yu Q, Zhang Y, Wang H, Brash J, Chen H. Anti-fouling bioactive surfaces. Acta Biomaterialia. 2011;7(4):1550–7. pmid:21195214
- 77. Marconi W, Benvenuti F, Piozzi A. Covalent bonding of heparin to a vinyl copolymer for biomedical applications. Biomaterials. 1997;18(12):885–90. pmid:9184753
- 78. Tsurufuji S, Sugio K, Takemasa F. The role of glucocorticoid receptor and gene expression in the anti-inflammatory action of dexamethasone. Nature. 1979;280(5721):408–10. pmid:460415
- 79. Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol. 1990;20(11):2439–43. pmid:2253684